A similar clinical trial evaluated the AAV-mediated delivery of NGF in AD patients and revealed a conserved ability of degenerating brain regions to interact with the delivered GF, as evidenced by axonal sprouting and the activation of cell signaling, with no NGF-related adverse effects being reported [108]. This evidence concerns the gene NGF and Alzheimer disease.